Anathema or Useful? Application of Immunohistochemistry to the Diagnosis of Melanocytic Lesions

[1]  C. Magro,et al.  Expression of soluble adenylyl cyclase in lentigo maligna: use of immunohistochemistry with anti-soluble adenylyl cyclase antibody (R21) in diagnosis of lentigo maligna and assessment of margins. , 2012, Archives of pathology & laboratory medicine.

[2]  R. Lazova,et al.  P75 Nerve Growth Factor Receptor as a Useful Marker to Distinguish Spindle Cell Melanoma From Other Spindle Cell Neoplasms of Sun-Damaged Skin , 2012, The American Journal of dermatopathology.

[3]  C. Shea,et al.  Immunohistochemistry of melanocytic proliferations. , 2011, Archives of pathology & laboratory medicine.

[4]  J. Karamchandani,et al.  SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar , 2010, Journal of cutaneous pathology.

[5]  D. Ivan,et al.  Use of immunohistochemistry in the diagnosis of melanocytic lesions: applications and pitfalls. , 2010, Future oncology.

[6]  S. Tahan,et al.  Melanocytic nevi in pregnancy: histologic features and Ki‐67 proliferation index , 2009, Journal of cutaneous pathology.

[7]  C. Shea,et al.  Use of immunohistochemistry in melanocytic lesions , 2008, Journal of cutaneous pathology.

[8]  A. Patereli,et al.  G1 cell cycle regulators in congenital melanocytic nevi. Comparison with acquired nevi and melanomas , 2008, Journal of cutaneous pathology.

[9]  L. Chiriboga,et al.  Sox10: A Pan-Schwannian and Melanocytic Marker , 2008, The American journal of surgical pathology.

[10]  B. Chwirot,et al.  Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours , 2007, Melanoma research.

[11]  J. Gershenwald,et al.  Galectin-3 Expression Is Associated with Tumor Progression and Pattern of Sun Exposure in Melanoma , 2006, Clinical Cancer Research.

[12]  H. Skelton,et al.  Nuclear expression of the antiapoptotic protein survivin in malignant melanoma , 2006, Cancer.

[13]  Y. Hashimoto,et al.  Expression profiles of melanogenesis‐related genes and proteins in acquired melanocytic nevus , 2006, Journal of cutaneous pathology.

[14]  A. H. Diwan,et al.  Loss of claudin‐1 expression in tumor‐associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms , 2005, Journal of cutaneous pathology.

[15]  H. Kerl,et al.  Melan-A: Not a Helpful Marker in Distinction between Melanoma In Situ on Sun-Damaged Skin and Pigmented Actinic Keratosis , 2004, The American Journal of dermatopathology.

[16]  M. Piris,et al.  Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. , 2004, The American journal of pathology.

[17]  N. S. Mcnutt,et al.  S100A6 Protein Expression is Different in Spitz Nevi and Melanomas , 2003, Modern Pathology.

[18]  L. Lowe,et al.  Antibody to S100a6 protein is a sensitive immunohistochemical marker for neurothekeoma , 2003, Journal of cutaneous pathology.

[19]  V. Prieto,et al.  Desmoplastic and spindle cell melanomas express protein markers of the neural crest but not of later committed stages of Schwann cell differentiation , 2002, Journal of cutaneous pathology.

[20]  V. Prieto,et al.  Atypical cells in human cutaneous re‐excision scars for melanoma express p75NGFR, C56/N‐CAM and GAP‐43: evidence of early Schwann cell differentiation , 2002, Journal of cutaneous pathology.

[21]  M. Mihm,et al.  Microphthalmia Transcription Factor Expression in Cutaneous Benign, Malignant Melanocytic, and Nonmelanocytic Tumors , 2001, The American journal of surgical pathology.

[22]  A. Folpe,et al.  Microphthalmia Transcription Factor and Melanoma Cell Adhesion Molecule Expression Distinguish Desmoplastic/Spindle Cell Melanoma From Morphologic Mimics , 2001, The American journal of surgical pathology.

[23]  C. Shea,et al.  Desmoplastic (sclerotic) nevus: an underrecognized entity that resembles dermatofibroma and desmoplastic melanoma. , 1999, The American journal of surgical pathology.

[24]  N. S. Mcnutt,et al.  The S100 family of multipurpose calcium‐binding proteins , 1998, Journal of cutaneous pathology.

[25]  Yao-Tseng Chen,et al.  Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. , 1998, The American journal of surgical pathology.

[26]  F. Marincola,et al.  Comparison of melanoma antigen recognized by T cells (MART-1) to HMB-45: additional evidence to support a common lineage for angiomyolipoma, lymphangiomyomatosis, and clear cell sugar tumor. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[27]  W. Gerald,et al.  A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. , 1998, The American journal of surgical pathology.

[28]  R. Parwaresch,et al.  Proliferation marker Ki-S5 as a diagnostic tool in melanocytic lesions. , 1997, Journal of the American Academy of Dermatology.

[29]  N. S. Mcnutt,et al.  The intermediate filament peripherin is expressed in cutaneous melanocytic lesions , 1997, Journal of cutaneous pathology.

[30]  N. S. Mcnutt,et al.  Nevoid malignant melanoma: morphologic patterns and immunohistochemical reactivity , 1995, Journal of cutaneous pathology.

[31]  F. Haluska,et al.  Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. , 1995, Cancer research.

[32]  A. Cochran,et al.  Immunohistpchemical demonstration of S‐100 protein and melanoma‐associated antigens in melanocytic nevi , 1988, Journal of cutaneous pathology.